App function and lipids: A bidirectional link

Frontiers in Molecular Neuroscience

Volumn 10, Issue , 2017, Pages

  Grimm, Marcus O W ^a   Mett, Janine ^a   Grimm, Heike S ^a   Hartmann, Tobias ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Abeta cholesterol; AICD; APP processing; Gangliosides; Lipids; PUFA; Sphingolipids; Sulfatides

Indexed keywords

AMYLOID BETA PROTEIN; CERAMIDE; DOCOSAHEXAENOIC ACID; GANGLIOSIDE; INSULINASE; PLASMALOGEN; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE;

ALZHEIMER DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; LIPID HOMEOSTASIS; LIPID METABOLISM; LIPID PEROXIDATION; MOLECULARLY TARGETED THERAPY; NERVE DEGENERATION; PHYSIOLOGY; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

EID: 85015630551     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2017.00063     Document Type: Review

References (260)

1. Abramov, A. Y., Ionov, M., Pavlov, E., and Duchen, M. R. (2011). Membrane cholesterol content plays a key role in the neurotoxicity of β-amyloid: implications for Alzheimer’s disease. Aging Cell 10, 595–603. doi: 10.1111/j.1474-9726.2011.00685.x
2. Arendash, G. W., Jensen, M. T., Salem, N. Jr., Hussein, N., Cracchiolo, J., Dickson, A., et al. (2007). A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer’s transgenic mice. Neuroscience 149, 286–302. doi: 10.1016/j.neuroscience.2007.08.018
3. Arvanitakis, Z., Schneider, J. A., Wilson, R. S., Bienias, J. L., Kelly, J. F., Evans, D. A., et al. (2008). Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795–1802. doi: 10.1212/01.wnl.0000288181.00826.63
4. Bandaru, V. V., Troncoso, J., Wheeler, D., Pletnikova, O., Wang, J., Conant, K., et al. (2009). ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain. Neurobiol. Aging 30, 591–599. doi: 10.1016/j. neurobiolaging.2007.07.024
5. Barberger-Gateau, P., Letenneur, L., Deschamps, V., Pérès, K., Dartigues, J. F., and Renaud, S. (2002). Fish, meat, and risk of dementia: cohort study. BMJ 325, 932–933. doi: 10.1136/bmj.325.7370.932
6. Barnes, D. E., and Yaffe, K. (2011). The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 10, 819–828. doi: 10.1016/S1474-4422(11)70072-2
7. Baulac, S., LaVoie, M. J., Kimberly, W. T., Strahle, J., Wolfe, M. S., Selkoe, D. J., et al. (2003). Functional γ-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2 and γ-secretase substrates. Neurobiol. Dis. 14, 194–204. doi: 10.1016/s0969-9961(03) 00123-2
8. Bernardo, A., Harrison, F. E., McCord, M., Zhao, J., Bruchey, A., Davies, S. S., et al. (2009). Elimination of GD3 synthase improves memory and reduces amyloid-β plaque load in transgenic mice. Neurobiol. Aging 30, 1777–1791. doi: 10.1016/j. neurobiolaging.2007.12.022
9. Bhardwaj, S., Passi, S. J., and Misra, A. (2011). Overview of trans fatty acids: biochemistry and health effects. Diabetes Metab. Syndr. 5, 161–164. doi: 10.1016/j.dsx.2012.03.002
10. Blank, M. L., Cress, E. A., Smith, Z. L., and Snyder, F. (1992). Meats and fish consumed in the American diet contain substantial amounts of ether-linked phospholipids. J. Nutr. 122, 1656–1661.
11. Braverman, N. E., and Moser, A. B. (2012). Functions of plasmalogen lipids in health and disease. Biochim. Biophys. Acta 1822, 1442–1452. doi: 10.1016/j. bbadis.2012.05.008
12. Breitner, J. C., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., et al. (1999). APOE-ε4 count predicts age when prevalence of AD increases, then declines: the cache county study. Neurology 53, 321–331. doi: 10.1212/WNL.53.2.321
13. Broniec, A., Klosinski, R., Pawlak, A., Wrona-Krol, M., Thompson, D., and Sarna, T. (2011). Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systems. Free Radic. Biol. Med. 50, 892–898. doi: 10.1016/j.freeradbiomed.2011.01.002
14. Brown, D. A., and Rose, J. K. (1992). Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68, 533–544. doi: 10.1016/0092-8674(92)90189-j
15. Brown, M. S., Ye, J., Rawson, R. B., and Goldstein, J. L. (2000). Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391–398. doi: 10.1016/s0092-8674(00)80675-3
16. Busam, K., and Decker, K. (1986). Ganglioside biosynthesis in rat liver. Characterization of three sialyltransferases. Eur. J. Biochem. 160, 23–30. doi: 10.1111/j.1432-1033.1986.tb09934.x
17. Cai, Z., Zhao, B., and Ratka, A. (2011). Oxidative stress and β-amyloid protein in Alzheimer’s disease. Neuromolecular Med. 13, 223–250. doi: 10.1007/s12017-011-8155-9
18. Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., et al. (2004). Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 43, 633–645. doi: 10.1016/j.neuron.2004.08.013
19. Cao, X., and Südhof, T. C. (2001). A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115–120. doi: 10.1126/science.1058783
20. Carey, R. M., Balcz, B. A., Lopez-Coviella, I., and Slack, B. E. (2005). Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid β protein. BMC Cell Biol. 6:30. doi: 10.1186/1471-2121-6-30
21. Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., Demattos, R. B., Patterson, B. W., et al. (2011). Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3:89ra57. doi: 10.1126/scitranslmed.3002156
22. Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., et al. (2012). Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287, 2678–2688. doi: 10.1074/jbc.M111.274142
23. Cheng, H., Wang, M., Li, J.-L., Cairns, N. J., and Han, X. (2013). Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer’s disease: an early event in disease pathogenesis. J. Neurochem. 127, 733–738. doi: 10.1111/jnc.12368
24. Cheng, H., Zhou, Y., Holtzman, D. M., and Han, X. (2010). Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer’s disease. Neurobiol. Aging 31, 1188–1196. doi: 10.1016/j.neurobiolaging.2008.07.020
25. Chiu, C. C., Su, K.-P., Cheng, T.-C., Liu, H.-C., Chang, C.-J., Dewey, M. E., et al. (2008). The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1538–1544. doi: 10.1016/j.pnpbp.2008.05.015
26. Choo-Smith, L.-P., Garzon-Rodriguez, W., Glabe, C. G., and Surewicz, W. K. (1997). Acceleration of amyloid fibril formation by specific binding of Aβ-(1–40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272, 22987–22990. doi: 10.1074/jbc.272.37.22987
27. Cibickova, L., Hyspler, R., Micuda, S., Cibicek, N., Zivna, H., Jun, D., et al. (2009). The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid β and cholesterol synthesis in rat brain. Steroids 74, 13–19. doi: 10.1016/j.steroids.2008.08.007
28. Collison, K. S., Makhoul, N. J., Inglis, A., Al-Johi, M., Zaidi, M. Z., Maqbool, Z., et al. (2010). Dietary trans-fat combined with monosodium glutamate induces dyslipidemia and impairs spatial memory. Physiol. Behav. 99, 334–342. doi: 10.1016/j.physbeh.2009.11.010
29. Conquer, J. A., Tierney, M. C., Zecevic, J., Bettger, W. J., and Fisher, R. H. (2000). Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids 35, 1305–1312. doi: 10.1007/s11745-000-0646-3
30. Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C. Jr., et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset alzheimer disease. Nat. Genet. 7, 180–184. doi: 10.1038/ng 0694-180
31. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923. doi: 10.1126/science.8346443
32. Cossec, J. C., Simon, A., Marquer, C., Moldrich, R. X., Leterrier, C., Rossier, J., et al. (2010). Clathrin-dependent APP endocytosis and Aβ secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim. Biophys. Acta 1801, 846–852. doi: 10.1016/j.bbalip.2010.05.010
33. Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., et al. (2004). Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 101, 2070–2075. doi: 10.1073/pnas.0305799101
34. Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S., et al. (1996). Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381, 800–803. doi: 10.1038/381800a0
35. Czubowicz, K., and Strosznajder, R. (2014). Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate. Mol. Neurobiol. 50, 26–37. doi: 10.1007/s12035-013-8606-4
36. Dawson, G., Goswami, R., Kilkus, J., Wiesner, D., and Dawson, S. (1998). The formation of ceramide from sphingomyelin is associated with cellular apoptosis. Acta Biochim. Pol. 45, 287–297.
37. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., et al. (2008). apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002–4013. doi: 10.1172/JCI36663
38. De Strooper, B. (2010). Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 90, 465–494. doi: 10.1152/physrev.00023.2009
39. De Vet, E. C., Ijlst, L., Oostheim, W., Dekker, C., Moser, H. W., van Den Bosch, H., et al. (1999). Ether lipid biosynthesis: alkyl-dihydroxyacetonephosphate synthase protein deficiency leads to reduced dihydroxyacetonephosphate acyltransferase activities. J. Lipid Res. 40, 1998–2003.
40. Devore, E. E., Stampfer, M. J., Breteler, M. M., Rosner, B., Kang, J. H., Okereke, O., et al. (2009). Dietary fat intake and cognitive decline in women with type 2 diabetes. Diabetes Care 32, 635–640. doi: 10.2337/dc08-1741
41. Dickerson, B. C., Goncharova, I., Sullivan, M. P., Forchetti, C., Wilson, R. S., Bennett, D. A., et al. (2001). MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiol. Aging 22, 747–754. doi: 10.1016/s0197-4580(01)00271-8
42. Dietschy, J. M., and Turley, S. D. (2004). Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375–1397. doi: 10.1194/jlr.R400004-JLR200
43. Di Paolo, G., and Kim, T. W. (2011). Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat. Rev. Neurosci. 12, 284–296. doi: 10.1038/nrn3012
44. Edbauer, D., Winkler, E., Regula, J. T., Pesold, B., Steiner, H., and Haass, C. (2003). Reconstitution of γ-secretase activity. Nat. Cell Biol. 5, 486–488. doi: 10.1038/ncb960
45. Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003). Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113–123. doi: 10.1083/jcb.200207113
46. Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., Van Swieten, J. C., Hofman, A., Witteman, J. C., et al. (2002). Diet and risk of dementia: does fat matter? the rotterdam study. Neurology 59, 1915–1921. doi: 10.1212/01.wnl.0000038345.77753.46
47. Fam, S. S., Murphey, L. J., Terry, E. S., Zackert, W. E., Chen, Y., Gao, L., et al. (2002). Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 277, 36076–36084. doi: 10.1074/jbc.m205638200
48. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces levels of Alzheimer’s disease β -amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U S A 98, 5856–5861. doi: 10.1073/pnas.081620098
49. Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., et al. (2010). Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956–964. doi: 10.1212/WNL.0b013e3181d6476a
50. Ferrera, P., Mercado-Gómez, O., Silva-Aguilar, M., Valverde, M., and Arias, C. (2008). Cholesterol potentiates β-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem. Res. 33, 1509–1517. doi: 10.1007/s11064-008-9623-y
51. Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., and Federoff, H. J. (2014). The critical need for defining preclinical biomarkers in Alzheimer’s disease. Alzheimers Dement. 10, S196–S212. doi: 10.1016/j.jalz.2014.04.015
52. Filippov, V., Song, M. A., Zhang, K., Vinters, H. V., Tung, S., Kirsch, W. M., et al. (2012). Increased ceramide in brains with Alzheimer’s and other neurodegenerative diseases. J. Alzheimers Dis. 29, 537–547. doi: 10.3233/JAD-2011-111202
53. Foley, P. (2010). Lipids in Alzheimer’s disease: a century-old story. Biochim. Biophys. Acta 1801, 750–753. doi: 10.1016/j.bbalip.2010.05.004
54. Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., et al. (2006). ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63, 1402–1408. doi: 10.1001/archneur.63.10.1402
55. Freund-Levi, Y., Hjorth, E., Lindberg, C., Cederholm, T., Faxen-Irving, G., Vedin, I., et al. (2009). Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study. Dement. Geriatr. Cogn. Disord. 27, 481–490. doi: 10.1159/000218081
56. Funamoto, S., Morishima-Kawashima, M., Tanimura, Y., Hirotani, N., Saido, T. C., and Ihara, Y. (2004). Truncated carboxyl-terminal fragments of β-amyloid precursor protein are processed to amyloid β-proteins 40 and 42. Biochemistry 43, 13532–13540. doi: 10.1021/bi049399k
57. Ginsberg, L., Rafique, S., Xuereb, J. H., Rapoport, S. I., and Gershfeld, N. L. (1995). Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res. 698, 223–226. doi: 10.1016/0006-8993(95)00931-f
58. Glenner, G. G. (1989). Amyloid β protein and the basis for Alzheimer’s disease. Prog. Clin. Biol. Res. 317, 857–868.
59. Glenner, G. G., and Wong, C. W. (1984). Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885–890. doi: 10.1016/s0006-291x(84)80190-4
60. Goedert, M., Strittmatter, W. J., and Roses, A. D. (1994). Alzheimer’s disease. Risky apolipoprotein in brain. Nature 372, 45–46. doi: 10.1038/37 2045a0
61. Gomez-Brouchet, A., Pchejetski, D., Brizuela, L., Garcia, V., Altié, M. F., Maddelein, M. L., et al. (2007). Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-β peptide. Mol. Pharmacol. 72, 341–349. doi: 10.1124/mol.106.033738
62. Gómez-Isla, T., Price, J. L., McKeel, D. W. Jr., Morris, J. C., Growdon, J. H., and Hyman, B. T. (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J. Neurosci. 16, 4491–4500.
63. Goodenowe, D. B., Cook, L. L., Liu, J., Lu, Y., Jayasinghe, D. A., Ahiahonu, P. W., et al. (2007). Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J. Lipid Res. 48, 2485–2498. doi: 10.1194/jlr.p700023-jlr200
64. Gottfries, C. G., Karlsson, I., and Svennerholm, L. (1996). Membrane components separate early-onset alzheimer’s disease from senile dementia of the Alzheimer type. Int. Psychogeriatr. 8, 365–372. doi: 10.1017/s1041610296002736
65. Grbovic, O. M., Mathews, P. M., Jiang, Y., Schmidt, S. D., Dinakar, R., Summers-Terio, N. B., et al. (2003). Rab5-stimulated up-regulation of the endocytic pathway increases intracellular β-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Aβ production. J. Biol. Chem. 278, 31261–31268. doi: 10.1074/jbc.M304122200
66. Green, K. N., Martinez-Coria, H., Khashwji, H., Hall, E. B., Yurko-Mauro, K. A., Ellis, L., et al. (2007). Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 27, 4385–4395. doi: 10.1523/JNEUROSCI.0055-07.2007
67. Grimm, M. O. W., Grimm, H. S., Pätzold, A. J., Zinser, E. G., Halonen, R., Duering, M., et al. (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat. Cell Biol. 7, 1118–1123. doi: 10.1038/ncb1313
68. Grimm, M. O. W., Grimm, H. S., Tomic, I., Beyreuther, K., Hartmann, T., and Bergmann, C. (2008). Independent inhibition of Alzheimer disease β-and γ-secretase cleavage by lowered cholesterol levels. J. Biol. Chem. 283, 11302–11311. doi: 10.1074/jbc.M801520200
69. Grimm, M. O. W., Grösgen, S., Riemenschneider, M., Tanila, H., Grimm, H. S., and Hartmann, T. (2011a). From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer’s disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A 1218, 7713–7722. doi: 10.1016/j.chroma.2011. 07.073
70. Grimm, M. O. W., Grösgen, S., Rothhaar, T. L., Burg, V. K., Hundsdörfer, B., Haupenthal, V. J., et al. (2011b). Intracellular APP domain regulates serine-palmitoyl-CoA transferase expression and is affected in Alzheimer’s disease. Int. J. Alzheimers Dis. 2011:695413. doi: 10.4061/2011/695413
71. Grimm, M. O. W., Kuchenbecker, J., Grösgen, S., Burg, V. K., Hundsdörfer, B., Rothhaar, T. L., et al. (2011c). Docosahexaenoic acid reduces amyloid β production via multiple pleiotropic mechanisms. J. Biol. Chem. 286, 14028–14039. doi: 10.1074/jbc.M110.182329
72. Grimm, M. O. W., Kuchenbecker, J., Rothhaar, T. L., Grösgen, S., Hundsdörfer, B., Burg, V. K., et al. (2011d). Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer’s disease. J. Neurochem. 116, 916–925. doi: 10.1111/j.1471-4159.2010.07070.x
73. Grimm, M. O. W., and Hartmann, T. (2012). Recent understanding of the molecular mechanisms of Alzheimer’s disease. J. Addict. Res. Ther. S5:004. doi: 10.4172/2155-6105.s5-004
74. Grimm, M. O. W., Haupenthal, V. J., Mett, J., Stahlmann, C. P., Blümel, T., Mylonas, N. T., et al. (2016a). Oxidized docosahexaenoic acid species and lipid peroxidation products increase amyloidogenic amyloid precursor protein processing. Neurodegener. Dis. 16, 44–54. doi: 10.1159/0004 40839
75. Grimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Blümel, T., Stötzel, H., et al. (2016b). Eicosapentaenoic acid and docosahexaenoic acid increase the degradation of amyloid-β by affecting insulin-degrading enzyme. Biochem. Cell Biol. 94, 534–542. doi: 10.1139/bcb-2015-0149
76. Grimm, M. O. W., Regner, L., Mett, J., Stahlmann, C. P., Schorr, P., Nelke, C., et al. (2016c). Tocotrienol affects oxidative stress, cholesterol homeostasis and the amyloidogenic pathway in neuroblastoma cells: consequences for Alzheimer’s disease. Int. J. Mol. Sci. 17:E1809. doi: 10.3390/ijms17111809
77. Grimm, M. O. W., Hundsdörfer, B., Grösgen, S., Mett, J., Zimmer, V. Z., Stahlmann, C. P., et al. (2014). PS dependent APP cleavage regulates glucosylceramide synthase and is affected in Alzheimer’s disease. Cell. Physiol. Biochem. 34, 92–110. doi: 10.1159/000362987
78. Grimm, M. O. W., Mett, J., Stahlmann, C. P., Grösgen, S., Haupenthal, V. J., Blümel, T., et al. (2015a). APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression. Front. Aging Neurosci. 7:77. doi: 10.3389/fnagi.2015.00077
79. Grimm, M. O. W., Stahlmann, C. P., Mett, J., Haupenthal, V. J., Zimmer, V. C., Lehmann, J., et al. (2015b). Vitamin E: curse or benefit in Alzheimer’s disease? A systematic investigation of the impact of α-, γ- and δ-tocopherol on Aβ generation and degradation in neuroblastoma cells. J. Nutr. Health Aging 19, 646–656. doi: 10.1007/s12603-015-0506-z
80. Grimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., and Hartmann, T. (2013). Neprilysin and Aβ clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer’s disease. Front. Aging Neurosci. 5:98. doi: 10.3389/fnagi.2013.00098
81. Grimm, M. O. W., Rothhaar, T. L., Grösgen, S., Burg, V. K., Hundsdörfer, B., Haupenthal, V. J., et al. (2012a). Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). J. Nutr. Biochem. 23, 1214–1223. doi: 10.1016/j.jnutbio.2011.06.015
82. Grimm, M. O. W., Rothhaar, T. L., and Hartmann, T. (2012b). The role of APP proteolytic processing in lipid metabolism. Exp. Brain Res. 217, 365–375. doi: 10.1007/s00221-011-2975-6
83. Grimm, M. O. W., Zinser, E. G., Grösgen, S., Hundsdorfer, B., Rothhaar, T. L., Burg, V. K., et al. (2012c). Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer’s disease pathology with ganglioside metabolism. PLoS One 7:e34095. doi: 10.1371/journal.pone.0034095
84. Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., and Wisniewski, H. M. (1986a). Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084–6089.
85. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986b). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U S A 83, 4913–4917. doi: 10.1073/pnas.83.13.4913
86. Grziwa, B., Grimm, M. O. W., Masters, C. L., Beyreuther, K., Hartmann, T., and Lichtenthaler, S. F. (2003). The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. J. Biol. Chem. 278, 6803–6808. doi: 10.1074/jbc.M210047200
87. Haag, M. D., Hofman, A., Koudstaal, P. J., Stricker, B. H., and Breteler, M. M. (2009). Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The rotterdam study. J. Neurol. Neurosurg. Psychiatry 80, 13–17. doi: 10.1136/jnnp.2008.150433
88. Haass, C., Koo, E. H., Mellon, A., Hung, A. Y., and Selkoe, D. J. (1992). Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500–503. doi: 10.1038/357500a0
89. Han, X. (2010). The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-β peptides and sulfatides in Alzheimer’s disease. Mol. Neurobiol. 41, 97–106. doi: 10.1007/s12035-009-8092-x
90. Han, X., Cheng, H., Fryer, J. D., Fagan, A. M., and Holtzman, D. M. (2003a). Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. J. Biol. Chem. 278, 8043–8051. doi: 10.1074/jbc.M212340200
91. Han, X., Fagan, A. M., Cheng, H., Morris, J. C., Xiong, C., and Holtzman, D. M. (2003b). Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann. Neurol. 54, 115–119. doi: 10.1002/ana.10618
92. Han, X., Holtzman, D. M., and McKeel, D. W. Jr. (2001). Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77, 1168–1180. doi: 10.1046/j.1471-4159.2001.00332.x
93. Han, X., Holtzman, D. M., McKeel, D. W. Jr., Kelley, J., and Morris, J. C. (2002). Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J. Neurochem. 82, 809–818. doi: 10.1046/j.1471-4159.2002.00997.x
94. Hao, M., Mukherjee, S., and Maxfield, F. R. (2001). Cholesterol depletion induces large scale domain segregation in living cell membranes. Proc. Natl. Acad. Sci. U S A 98, 13072–13077. doi: 10.1073/pnas.231377398
95. Hardy, J. A., and Higgins, G. A. (1992). Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185. doi: 10.1126/science.1566067
96. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356. doi: 10.1126/science.1072994
97. Harris, B., Pereira, I., and Parkin, E. (2009). Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. Brain Res. 1296, 203–215. doi: 10.1016/j.brainres.2009.07.105
98. Hashimoto, M., Hossain, S., Agdul, H., and Shido, O. (2005a). Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid β-infused rats relates to the decreases of amyloid β and cholesterol levels in detergent-insoluble membrane fractions. Biochim. Biophys. Acta 1738, 91–98. doi: 10.1016/j.bbalip.2005.11.011
99. Hashimoto, M., Tanabe, Y., Fujii, Y., Kikuta, T., Shibata, H., and Shido, O. (2005b). Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid β-infused rats. J. Nutr. 135, 549–555.
100. Hashimoto, M., Hossain, S., Shimada, T., Sugioka, K., Yamasaki, H., Fujii, Y., et al. (2002). Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer’s disease model rats. J. Neurochem. 81, 1084–1091. doi: 10.1046/j.1471-4159.2002.00905.x
101. Hayashi, H., Kimura, N., Yamaguchi, H., Hasegawa, K., Yokoseki, T., Shibata, M., et al. (2004). A seed for Alzheimer amyloid in the brain. J. Neurosci. 24, 4894–4902. doi: 10.1523/JNEUROSCI.0861-04.2004
102. He, X., Huang, Y., Li, B., Gong, C. X., and Schuchman, E. H. (2010). Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol. Aging 31, 398–408. doi: 10.1016/j.neurobiolaging.2008.05.010
103. Hicks, D. A., Nalivaeva, N. N., and Turner, A. J. (2012). Lipid rafts and Alzheimer’s disease: protein-lipid interactions and perturbation of signaling. Front. Physiol. 3:189. doi: 10.3389/fphys.2012.00189
104. Hjorth, E., Zhu, M., Toro, V. C., Vedin, I., Palmblad, J., Cederholm, T., et al. (2013). Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J. Alzheimers Dis. 35, 697–713. doi: 10.3233/JAD-130131
105. Holmes, O., Paturi, S., Ye, W., Wolfe, M. S., and Selkoe, D. J. (2012). Effects of membrane lipids on the activity and processivity of purified γ-secretase. Biochemistry 51, 3565–3575. doi: 10.1021/bi300303g
106. Holtzman, D. M., Herz, J., and Bu, G. (2012). Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2:a006312. doi: 10.1101/cshperspect.a006312
107. Horrocks, L. A., and Farooqui, A. A. (2004). Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot. Essent. Fatty Acids 70, 361–372. doi: 10.1016/j.plefa.2003.12.011
108. Hossain, S., Hashimoto, M., Katakura, M., Miwa, K., Shimada, T., and Shido, O. (2009). Mechanism of docosahexaenoic acid-induced inhibition of in vitro Aβ1–42 fibrillation and Aβ1–42-induced toxicity in SH-S5Y5 cells. J. Neurochem. 111, 568–579. doi: 10.1111/j.1471-4159.2009.06336.x
109. Huang, Y., Tanimukai, H., Liu, F., Iqbal, K., Grundke-Iqbal, I., and Gong, C. X. (2004). Elevation of the level and activity of acid ceramidase in Alzheimer’s disease brain. Eur. J. Neurosci. 20, 3489–3497. doi: 10.1111/j.1460-9568.2004.03852.x
110. Ibrahim, A., Natrajan, S., and Ghafoorunissa, R. (2005). Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. Metabolism 54, 240–246. doi: 10.1016/j.metabol.2004.08.019
111. Igarashi, M., Ma, K., Gao, F., Kim, H. W., Rapoport, S. I., and Rao, J. S. (2011). Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer’s disease prefrontal cortex. J. Alzheimers Dis. 24, 507–517. doi: 10.3233/JAD-2011-101608
112. Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and Ihara, Y. (1994). Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 45–53. doi: 10.1016/0896-6273(94)90458-8
113. Jana, A., and Pahan, K. (2004). Fibrillar amyloid-β peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer’s disease. J. Biol. Chem. 279, 51451–51459. doi: 10.1074/jbc.M404635200
114. Jarrett, J. T., Berger, E. P., and Lansbury, P. T. Jr. (1993). The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 4693–4697. doi: 10.1021/bi00069a001
115. Jicha, G. A., and Markesbery, W. R. (2010). Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease. Clin. Interv. Aging 5, 45–61. doi: 10.2147/cia.s5231
116. Judd, J. T., Clevidence, B. A., Muesing, R. A., Wittes, J., Sunkin, M. E., and Podczasy, J. J. (1994). Dietary trans fatty acids: effects on plasma lipids and lipoproteins of healthy men and women. Am. J. Clin. Nutr. 59, 861–868.
117. Kakuda, N., Funamoto, S., Yagishita, S., Takami, M., Osawa, S., Dohmae, N., et al. (2006). Equimolar production of amyloid β-protein and amyloid precursor protein intracellular domain from β-carboxyl-terminal fragment by γ-secretase. J. Biol. Chem. 281, 14776–14786. doi: 10.1074/jbc.m513453200
118. Kalanj, S., Kracun, I., Rosner, H., and Cosović, C. (1991). Regional distribution of brain gangliosides in Alzheimer’s disease. Neurol. Croat. 40, 269–281.
119. Kalmijn, S., Launer, L. J., Ott, A., Witteman, J. C., Hofman, A., and Breteler, M. M. (1997). Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann. Neurol. 42, 776–782. doi: 10.1002/ana.410420514
120. Kalvodova, L., Kahya, N., Schwille, P., Ehehalt, R., Verkade, P., Drechsel, D., et al. (2005). Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem. 280, 36815–36823. doi: 10.1074/jbc.M504484200
121. Kamal-Eldin, A., and Appelqvist, L. A. (1996). The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 31, 671–701. doi: 10.1007/bf02522884
122. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., et al. (1987). The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733–736. doi: 10.1038/325733a0
123. Karaca, I., Tamboli, I. Y., Glebov, K., Richter, J., Fell, L. H., Grimm, M. O. W., et al. (2014). Deficiency of Sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein. J. Biol. Chem. 289, 16761–16772. doi: 10.1074/jbc.m113.535500
124. Katsel, P., Li, C., and Haroutunian, V. (2007). Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem. Res. 32, 845–856. doi: 10.1007/s11064-007-9297-x
125. Kimberly, W. T., LaVoie, M. J., Ostaszewski, B. L., Ye, W., Wolfe, M. S., and Selkoe, D. J. (2003). γ-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1 and Pen-2. Proc. Natl. Acad. Sci. U S A 100, 6382–6387. doi: 10.1073/pnas.1037392100
126. Kivipelto, M., Helkala, E. L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., et al. (2002). Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137, 149–155. doi: 10.7326/0003-4819-137-3-200208060-00006
127. Ko, M. H., and Puglielli, L. (2009). Two endoplasmic reticulum (ER)/ER Golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels. J. Biol. Chem. 284, 2482–2492. doi: 10.1074/jbc. m804901200
128. Koivisto, H., Grimm, M. O. W., Rothhaar, T. L., Berkecz, R., Lütjohann, D. D., Giniatullina, R., et al. (2014). Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer’s disease independent of brain amyloid deposition. J. Nutr. Biochem. 25, 157–169. doi: 10.1016/j.jnutbio.2013.09.015
129. Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. (2001). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. U S A 98, 5815–5820. doi: 10.1073/pnas.081612998
130. Kölzer, M., Werth, N., and Sandhoff, K. (2004). Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 559, 96–98. doi: 10.1016/s0014-5793(04)00033-x
131. Koo, E. H., and Squazzo, S. L. (1994). Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386–17389.
132. Kornhuber, J., Tripal, P., Reichel, M., Terfloth, L., Bleich, S., Wiltfang, J., et al. (2008). Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J. Med. Chem. 51, 219–237. doi: 10.1021/jm070524a
133. Kosicek, M., Zetterberg, H., Andreasen, N., Peter-Katalinic, J., and Hecimovic, S. (2012). Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer’s disease. Neurosci. Lett. 516, 302–305. doi: 10.1016/j.neulet.2012.04.019
134. Kotani, S., Sakaguchi, E., Warashina, S., Matsukawa, N., Ishikura, Y., Kiso, Y., et al. (2006). Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci. Res. 56, 159–164. doi: 10.1016/j. neures.2006.06.010
135. Kracun, I., Rosner, H., Drnovsek, V., Heffer-Lauc, M., Cosović, C., and Lauc, G. (1991). Human brain gangliosides in development, aging and disease. Int. J. Dev. Biol. 35, 289–295.
136. Kröger, E., Verreault, R., Carmichael, P. H., Lindsay, J., Julien, P., Dewailly, E., et al. (2009). Omega-3 fatty acids and risk of dementia: the canadian study of health and aging. Am. J. Clin. Nutr. 90, 184–192. doi: 10.3945/ajcn.2008.26987
137. Kuhn, P. H., Wang, H., Dislich, B., Colombo, A., Zeitschel, U., Ellwart, J. W., et al. (2010). ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO J. 29, 3020–3032. doi: 10.1038/emboj.2010.167
138. Kurata, T., Kawai, H., Miyazaki, K., Kozuki, M., Morimoto, N., Ohta, Y., et al. (2012). Statins have therapeutic potential for the treatment of Alzheimer’s disease, likely via protection of the neurovascular unit in the AD brain. J. Neurol. Sci. 322, 59–63. doi: 10.1016/j.jns.2012.06.011
139. Kuusisto, J., Koivisto, K., Kervinen, K., Mykkänen, L., Helkala, E. L., Vanhanen, M., et al. (1994). Association of apolipoprotein E phenotypes with late onset alzheimer’s disease: population based study. BMJ 309, 636–638. doi: 10.1136/bmj.309.6955.636
140. Lahiri, S., and Futerman, A. H. (2007). The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64, 2270–2284. doi: 10.1007/s00018-007-7076-0
141. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., et al. (1998). Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U S A 95, 6448–6453. doi: 10.1073/pnas.95.11.6448
142. Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., et al. (1999). Constitutive and regulated α-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U S A 96, 3922–3927. doi: 10.1073/pnas.96.7.3922
143. Laryea, M., Cieslicki, P., Diekmann, E., and Wendel, U. (1990). Age-dependent fatty acid composition of erythrocyte membrane phospholipids in healthy children. Z. Ernahrungswiss. 29, 284–294. doi: 10.1007/bf02023085
144. Lauritzen, L., Hansen, H. S., Jørgensen, M. H., and Michaelsen, K. F. (2001). The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 40, 1–94. doi: 10.1016/s0163-7827(00)00017-5
145. Lee, J., Culyba, E. K., Powers, E. T., and Kelly, J. W. (2011). Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat. Chem. Biol. 7, 602–609. doi: 10.1038/nchembio.624
146. Lee, S. J., Liyanage, U., Bickel, P. E., Xia, W., Lansbury, P. T. Jr., and Kosik, K. S. (1998). A detergent-insoluble membrane compartment contains Aβ in vivo. Nat. Med. 4, 730–734. doi: 10.1038/nm0698-730
147. Lee, J. T., Xu, J., Lee, J. M., Ku, G., Han, X., Yang, D. I., et al. (2004). Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol. 164, 123–131. doi: 10.1083/jcb.200307017
148. Lepine, S., Lakatos, B., Courageot, M. P., Le Stunff, H., Sulpice, J. C., and Giraud, F. (2004). Sphingosine contributes to glucocorticoid-induced apoptosis of thymocytes independently of the mitochondrial pathway. J. Immunol. 173, 3783–3790. doi: 10.4049/jimmunol.173.6.3783
149. Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357. doi: 10.1038/nature04533
150. Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., et al. (1990). Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124–1126. doi: 10.1126/science.2111584
151. Levy-Lahad, E., Wijsman, E. M., Nemens, E., Anderson, L., Goddard, K. A., Weber, J. L., et al. (1995). A familial Alzheimer’s disease locus on chromosome 1. Science 269, 970–973. doi: 10.1126/science.7638621
152. Lichtenthaler, S. F., Haass, C., and Steiner, H. (2011). Regulated intramembrane proteolysis–lessons from amyloid precursor protein processing. J. Neurochem. 117, 779–796. doi: 10.1111/j.1471-4159.2011.07248.x
153. Lim, G. P., Calon, F., Morihara, T., Yang, F., Teter, B., Ubeda, O., et al. (2005). A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 3032–3040. doi: 10.1523/JNEUROSCI.4225-04.2005
154. Lingwood, D., and Simons, K. (2010). Lipid rafts as a membrane-organizing principle. Science 327, 46–50. doi: 10.1126/science.1174621
155. Ma, J., Yee, A., Brewer, H. B. Jr., Das, S., and Potter, H. (1994). Amyloid-associated proteins α 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372, 92–94. doi: 10.1038/372092a0
156. Mahley, R. W., Nathan, B. P., and Pitas, R. E. (1996). Apolipoprotein E. Structure, function, and possible roles in Alzheimer’s disease. Ann. N Y Acad. Sci. 777, 139–145. doi: 10.1111/j.1749-6632.1996.tb34412.x
157. Malaplate-Armand, C., Florent-Béchard, S., Youssef, I., Koziel, V., Sponne, I., Kriem, B., et al. (2006). Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 23, 178–189. doi: 10.1016/j.nbd.2006.02.010
158. Mann, N. J., O’Connell, S. L., Baldwin, K. M., Singh, I., and Meyer, B. J. (2010). Effects of seal oil and tuna-fish oil on platelet parameters and plasma lipid levels in healthy subjects. Lipids 45, 669–681. doi: 10.1007/s11745-010-3450-z
159. Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., et al. (2014). Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20, 415–418. doi: 10.1038/nm.3466
160. Markesbery, W. R., and Lovell, M. A. (1998). Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol. Aging 19, 33–36. doi: 10.1016/s0197-4580(98)00009-8
161. Martins, I. J., Berger, T., Sharman, M. J., Verdile, G., Fuller, S. J., and Martins, R. N. (2009). Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease. J. Neurochem. 111, 1275–1308. doi: 10.1111/j.1471-4159.2009.06408.x
162. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U S A 82, 4245–4249. doi: 10.1073/pnas.82.12.4245
163. Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., et al. (2003). Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23, 29–33.
164. Matsuzaki, T., Sasaki, K., Hata, J., Hirakawa, Y., Fujimi, K., Ninomiya, T., et al. (2011). Association of Alzheimer disease pathology with abnormal lipid metabolism: the hisayama study. Neurology 77, 1068–1075. doi: 10.1212/WNL.0b013e31822e145d
165. Maulik, M., Westaway, D., Jhamandas, J. H., and Kar, S. (2013). Role of cholesterol in APP metabolism and its significance in Alzheimer’s disease pathogenesis. Mol. Neurobiol. 47, 37–63. doi: 10.1007/s12035-012-8337-y
166. McGuinness, B., Craig, D., Bullock, R., Malouf, R., and Passmore, P. (2014). Statins for the treatment of dementia. Cochrane Database Syst. Rev. 8:CD007514. doi: 10.1002/14651858.CD007514.pub3
167. Meng, X. F., Yu, J. T., Wang, H. F., Tan, M. S., Wang, C., Tan, C. C., et al. (2014). Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J. Alzheimers Dis. 42, 1295–1310. doi: 10.3233/JAD-140954
168. Mensink, R. P., and Katan, M. B. (1990). Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N. Engl. J. Med. 323, 439–445. doi: 10.1056/NEJM199008163230703
169. Mett, J., Hartmann, T., and Grimm, M. O. W. (2014). ‘‘The effects of glycerophospholipids and fatty acids on APP processing: implications for Alzheimer’s disease,’’ in Handbook of Lipids in Human Function, eds R. Ross Watson and F. De Meester, (Amsterdam: Academic Press), 377–421.
170. Mielke, M. M., Bandaru, V. V., Haughey, N. J., Xia, J., Fried, L. P., Yasar, S., et al. (2012). Serum ceramides increase the risk of Alzheimer disease: the women’s health and aging study II. Neurology 79, 633–641. doi: 10.1212/WNL.0b013e318264e380
171. Mielke, M. M., Haughey, N. J., Bandaru, V. V., Weinberg, D. D., Darby, E., Zaidi, N., et al. (2011). Plasma sphingomyelins are associated with cognitive progression in Alzheimer’s disease. J. Alzheimers Dis. 27, 259–269. doi: 10.3233/JAD-2011-110405
172. Molander-Melin, M., Blennow, K., Bogdanovic, N., Dellheden, B., Månsson, J. E., and Fredman, P. (2005). Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem. 92, 171–182. doi: 10.1111/j.1471-4159.2004. 02849.x
173. Montine, T. J., and Morrow, J. D. (2005). Fatty acid oxidation in the pathogenesis of Alzheimer’s disease. Am. J. Pathol. 166, 1283–1289. doi: 10.1016/s0002-9440(10)62347-4
174. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal, N., et al. (2003a). Dietary fats and the risk of incident Alzheimer disease. Arch. Neurol. 60, 194–200. doi: 10.1001/archneur.60.8.1072
175. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., et al. (2003b). Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 60, 940–946. doi: 10.1001/archneur.60.7.940
176. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., and Wilson, R. S. (2004). Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology 62, 1573–1579. doi: 10.1212/01.wnl.0000123250.82849.b6
177. Morris, M. C., Evans, D. A., Tangney, C. C., Bienias, J. L., Schneider, J. A., Wilson, R. S., et al. (2006). Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch. Neurol. 63, 1085–1088. doi: 10.1001/archneur.63.8.1085
178. Mouton, P. R., Martin, L. J., Calhoun, M. E., Dal Forno, G., and Price, D. L. (1998). Cognitive decline strongly correlates with cortical atrophy in Alzheimer’s dementia. Neurobiol. Aging 19, 371–377. doi: 10.1016/s0197-4580(98)00080-3
179. Muskiet, F. A., van Goor, S. A., Kuipers, R. S., Velzing-Aarts, F. V., Smit, E. N., Bouwstra, H., et al. (2006). Long-chain polyunsaturated fatty acids in maternal and infant nutrition. Prostaglandins Leukot. Essent. Fatty Acids 75, 135–144. doi: 10.1016/j.plefa.2006.05.010
180. Naqvi, A. Z., Harty, B., Mukamal, K. J., Stoddard, A. M., Vitolins, M., and Dunn, J. E. (2011). Monounsaturated, trans, and saturated Fatty acids and cognitive decline in women. J. Am. Geriatr. Soc. 59, 837–843. doi: 10.1111/j. 1532-5415.2011.03402.x
181. Nguyen, L. N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., et al. (2014). Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509, 503–506. doi: 10.1038/nature13241
182. Nishinaka, T., Iwata, D., Shimada, S., Kosaka, K., and Suzuki, Y. (1993). Anti-ganglioside GD1a monoclonal antibody recognizes senile plaques in the brains of patients with Alzheimer-type dementia. Neurosci. Res. 17, 171–176. doi: 10.1016/0168-0102(93)90093-6
183. Okada, T., Wakabayashi, M., Ikeda, K., and Matsuzaki, K. (2007). Formation of toxic fibrils of Alzheimer’s amyloid β-protein-(1–40) by monosialoganglioside GM1, a neuronal membrane component. J. Mol. Biol. 371, 481–489. doi: 10.1016/j.jmb.2007.05.069
184. Okereke, O. I., Rosner, B. A., Kim, D. H., Kang, J. H., Cook, N. R., Manson, J. E., et al. (2012). Dietary fat types and 4-year cognitive change in community-dwelling older women. Ann. Neurol. 72, 124–134. doi: 10.1002/ana.23593
185. Oma, S., Mawatari, S., Saito, K., Wakana, C., Tsuboi, Y., Yamada, T., et al. (2012). Changes in phospholipid composition of erythrocyte membrane in Alzheimer’s disease. Dement. Geriatr. Cogn. Dis. Extra 2, 298–303. doi: 10.1159/000341603
186. Onodera, T., Futai, E., Kan, E., Abe, N., Uchida, T., Kamio, Y., et al. (2015). Phosphatidylethanolamine plasmalogen enhances the inhibiting effect of phosphatidylethanolamine on γ-secretase activity. J. Biochem. 157, 301–309. doi: 10.1093/jb/mvu074
187. Osenkowski, P., Ye, W., Wang, R., Wolfe, M. S., and Selkoe, D. J. (2008). Direct and potent regulation of γ-secretase by its lipid microenvironment. J. Biol. Chem. 283, 22529–22540. doi: 10.1074/jbc.M801925200
188. Ouellet, M., Emond, V., Chen, C. T., Julien, C., Bourasset, F., Oddo, S., et al. (2009). Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem. Int. 55, 476–482. doi: 10.1016/j.neuint.2009.04.018
189. Panchal, M., Loeper, J., Cossec, J. C., Perruchini, C., Lazar, A., Pompon, D., et al. (2010). Enrichment of cholesterol in microdissected Alzheimer’s disease senile plaques as assessed by mass spectrometry. J. Lipid Res. 51, 598–605. doi: 10.1194/jlr.M001859
190. Pappolla, M. A., Bryant-Thomas, T. K., Herbert, D., Pacheco, J., Fabra Garcia, M., Manjon, M., et al. (2003). Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199–205. doi: 10.1212/01.wnl.0000070182.02537.84
191. Park, I. H., Hwang, E. M., Hong, H. S., Boo, J. H., Oh, S. S., Lee, J., et al. (2003). Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiol. Aging 24, 637–643. doi: 10.1016/s0197-4580(02)00155-0
192. Parvathy, S., Hussain, I., Karran, E. H., Turner, A. J., and Hooper, N. M. (1999). Cleavage of Alzheimer’s amyloid precursor protein by α-secretase occurs at the surface of neuronal cells. Biochemistry 38, 9728–9734. doi: 10.1021/bi9906827
193. Passer, B., Pellegrini, L., Russo, C., Siegel, R. M., Lenardo, M. J., Schettini, G., et al. (2000). Generation of an apoptotic intracellular peptide by γ-secretase cleavage of Alzheimer’s amyloid β protein precursor. J. Alzheimers Dis. 2, 289–301.
194. Pawlosky, R. J., Hibbeln, J. R., Novotny, J. A., and Salem, N. Jr. (2001). Physiological compartmental analysis of α-linolenic acid metabolism in adult humans. J. Lipid Res. 42, 1257–1265.
195. Perez, S. E., Berg, B. M., Moore, K. A., He, B., Counts, S. E., Fritz, J. J., et al. (2010). DHA diet reduces AD pathology in young APPswe/PS1 δ E9 transgenic mice: possible gender effects. J. Neurosci. Res. 88, 1026–1040. doi: 10.1002/jnr.22266
196. Pettegrew, J. W., Panchalingam, K., Hamilton, R. L., and McClure, R. J. (2001). Brain membrane phospholipid alterations in Alzheimer’s disease. Neurochem. Res. 26, 771–782. doi: 10.1023/A:1011603916962
197. Phivilay, A., Julien, C., Tremblay, C., Berthiaume, L., Julien, P., Giguère, Y., et al. (2009). High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-β and tau pathologies in the 3xTg-AD model of Alzheimer’s disease. Neuroscience 159, 296–307. doi: 10.1016/j.neuroscience.2008.12.006
198. Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., et al. (2007). Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125–132. doi: 10.1159/000109998
199. Polidori, M. C., Pientka, L., and Mecocci, P. (2012). A review of the major vascular risk factors related to Alzheimer’s disease. J. Alzheimers Dis. 32, 521–530. doi: 10.3233/JAD-2012-120871
200. Posse de Chaves, E., and Sipione, S. (2010). Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett. 584, 1748–1759. doi: 10.1016/j.febslet.2009.12.010
201. Puglielli, L., Ellis, B. C., Saunders, A. J., and Kovacs, D. M. (2003). Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis. J. Biol. Chem. 278, 19777–19783. doi: 10.1074/jbc.M300466200
202. Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., et al. (2005). Longer forms of amyloid β protein: implications for the mechanism of intramembrane cleavage by γ-secretase. J. Neurosci. 25, 436–445. doi: 10.1523/JNEUROSCI.1575-04.2005
203. Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., et al. (2010). Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304, 1903–1911. doi: 10.1001/jama.2010.1510
204. Rea, T. D., Breitner, J. C., Psaty, B. M., Fitzpatrick, A. L., Lopez, O. L., Newman, A. B., et al. (2005). Statin use and the risk of incident dementia: the cardiovascular health study. Arch. Neurol. 62, 1047–1051. doi: 10.1001/archneur.62.7.1047
205. Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., and Jagust, W. (2014). Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 71, 195–200. doi: 10.1001/jamaneurol.2013.5390
206. Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., et al. (2000). Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321–331. doi: 10.1006/nbdi.2000.0304
207. Refolo, L. M., Pappolla, M. A., Lafrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., et al. (2001). A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis. 8, 890–899. doi: 10.1006/nbdi.2001.0422
208. Ribeiro-Resende, V. T., Araujo Gomes, T., de Lima, S., Nascimento-Lima, M., Bargas-Rega, M., Santiago, M. F., et al. (2014). Mice lacking GD3 synthase display morphological abnormalities in the sciatic nerve and neuronal disturbances during peripheral nerve regeneration. PLoS One 9:e108919. doi: 10.1371/journal.pone.0108919
209. Riddell, D. R., Christie, G., Hussain, I., and Dingwall, C. (2001). Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr. Biol. 11, 1288–1293. doi: 10.1016/s0960-9822(01)00394-3
210. Roach, C., Feller, S. E., Ward, J. A., Shaikh, S. R., Zerouga, M., and Stillwell, W. (2004). Comparison of cis and trans fatty acid containing phosphatidylcholines on membrane properties. Biochemistry 43, 6344–6351. doi: 10.1021/bi 049917r
211. Rothhaar, T. L., Grösgen, S., Haupenthal, V. J., Burg, V. K., Hundsdörfer, B., Mett, J., et al. (2012). Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer’s disease. ScientificWorldJournal 2012:141240. doi: 10.1100/2012/141240
212. Saitoh, M., Itoh, M., Takashima, S., Mizuguchi, M., and Iwamori, M. (2009). Phosphatidyl ethanolamine with increased polyunsaturated fatty acids in compensation for plasmalogen defect in the Zellweger syndrome brain. Neurosci. Lett. 449, 164–167. doi: 10.1016/j.neulet.2008.11.004
213. Sanchez-Mejia, R. O., Newman, J. W., Toh, S., Yu, G. Q., Zhou, Y., Halabisky, B., et al. (2008). Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease. Nat. Neurosci. 11, 1311–1318. doi: 10.1038/nn.2213
214. Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., et al. (2011). A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77, 556–563. doi: 10.1212/WNL.0b013e318228bf11
215. Satoi, H., Tomimoto, H., Ohtani, R., Kitano, T., Kondo, T., Watanabe, M., et al. (2005). Astroglial expression of ceramide in Alzheimer’s disease brains: a role during neuronal apoptosis. Neuroscience 130, 657–666. doi: 10.1016/j.neuroscience.2004.08.056
216. Sayre, L. M., Zelasko, D. A., Harris, P. L., Perry, G., Salomon, R. G., and Smith, M. A. (1997). 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J. Neurochem. 68, 2092–2097. doi: 10.1046/j.1471-4159.1997.68052092.x
217. Scheff, S. W., and Price, D. A. (1993). Synapse loss in the temporal lobe in Alzheimer’s disease. Ann. Neurol. 33, 190–199. doi: 10.1002/ana.410330209
218. Schneider, A., Schulz-Schaeffer, W., Hartmann, T., Schulz, J. B., and Simons, M. (2006). Cholesterol depletion reduces aggregation of amyloid-β peptide in hippocampal neurons. Neurobiol. Dis. 23, 573–577. doi: 10.1016/j.nbd.2006.04.015
219. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 14, 837–842. doi: 10.1038/nm1782
220. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375, 754–760. doi: 10.1038/375754a0
221. Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., et al. (2014). Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front. Aging Neurosci. 6:71. doi: 10.3389/fnagi.2014.00071
222. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., and Simons, K. (1998). Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U S A 95, 6460–6464. doi: 10.1073/pnas.95.11.6460
223. Smith, M. A., Kutty, R. K., Richey, P. L., Yan, S. D., Stern, D., Chader, G. J., et al. (1994). Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer’s disease. Am. J. Pathol. 145, 42–47.
224. Söderberg, M., Edlund, C., Kristensson, K., and Dallner, G. (1991). Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids 26, 421–425. doi: 10.1007/bf02536067
225. Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., and Whitmer, R. A. (2009). Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 28, 75–80. doi: 10.1159/000231980
226. Sparks, D. L., Scheff, S. W., Hunsaker, J. C. III, Liu, H., Landers, T., and Gross, D. R. (1994). Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88–94. doi: 10.1006/exnr. 1994.1044
227. Stillwell, W., Shaikh, S. R., Zerouga, M., Siddiqui, R., and Wassall, S. R. (2005). Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod. Nutr. Dev. 45, 559–579. doi: 10.1051/rnd:2005046
228. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., et al. (1993). Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U S A 90, 1977–1981. doi: 10.1073/pnas.90.5.1977
229. Styger, R., Wiesmann, U. N., and Honegger, U. E. (2002). Plasmalogen content and β-adrenoceptor signalling in fibroblasts from patients with Zellweger syndrome. Effects of hexadecylglycerol. Biochim. Biophys. Acta 1585, 39–43. doi: 10.1016/s1388-1981(02)00320-7
230. Svennerholm, L., and Gottfries, C. G. (1994). Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 62, 1039–1047. doi: 10.1046/j.1471-4159.1994.6203 1039.x
231. Sweeney, E. A., Inokuchi, J., and Igarashi, Y. (1998). Inhibition of sphingolipid induced apoptosis by caspase inhibitors indicates that sphingosine acts in an earlier part of the apoptotic pathway than ceramide. FEBS Lett. 425, 61–65. doi: 10.1016/s0014-5793(98)00198-7
232. Takasugi, N., Sasaki, T., Suzuki, K., Osawa, S., Isshiki, H., Hori, Y., et al. (2011). BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J. Neurosci. 31, 6850–6857. doi: 10.1523/JNEUROSCI.6467-10.2011
233. Tamaoka, A., Sawamura, N., Odaka, A., Suzuki, N., Mizusawa, H., Shoji, S., et al. (1995). Amyloid β protein 1–42/43 (A β 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res. 679, 151–156. doi: 10.1016/0006-8993(95)00162-J
234. Tamboli, I. Y., Prager, K., Barth, E., Heneka, M., Sandhoff, K., and Walter, J. (2005). Inhibition of glycosphingolipid biosynthesis reduces secretion of the β-amyloid precursor protein and amyloid β-peptide. J. Biol. Chem. 280, 28110–28117. doi: 10.1074/jbc.M414525200
235. Tanzi, R. E. (2012). The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2:a006296. doi: 10.1101/cshperspect.a006296
236. Tarasiuk, J., Kapica-Topczewska, K., Kulakowska, A., Halicka, D., Drozdowski, W., Kornhuber, J., et al. (2012). Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report. J. Neural Transm. 119, 759–762. doi: 10.1007/s00702-012-0826-7
237. + -ATPase and catalase activity in rat striatum. Behav. Brain Res. 226, 504–510. doi: 10.1016/j.bbr.2011.10.005
238. Thinakaran, G., and Koo, E. H. (2008). Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615–29619. doi: 10.1074/jbc.R800019200
239. Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., and Corey-Bloom, J. (2004). Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62, 1977–1983. doi: 10.1212/01.wnl.0000128091.92139.0f
240. Toman, R. E., Movsesyan, V., Murthy, S. K., Milstien, S., Spiegel, S., and Faden, A. I. (2002). Ceramide-induced cell death in primary neuronal cultures: upregulation of ceramide levels during neuronal apoptosis. J. Neurosci. Res. 68, 323–330. doi: 10.1002/jnr.10190
241. Tully, A. M., Roche, H. M., Doyle, R., Fallon, C., Bruce, I., Lawlor, B., et al. (2003). Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case-control study. Br. J. Nutr. 89, 483–489. doi: 10.1079/BJN2002804
242. Umeda, T., Mori, H., Zheng, H., and Tomiyama, T. (2010). Regulation of cholesterol efflux by amyloid β secretion. J. Neurosci. Res. 88, 1985–1994. doi: 10.1002/jnr.22360
243. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., et al. (1999). β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741. doi: 10.1126/science.286.5440.735
244. Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., et al. (2004). Association of γ-secretase with lipid rafts in post-Golgi and endosome membranes. J. Biol. Chem. 279, 44945–44954. doi: 10.1074/jbc.m407986200
245. von Rotz, R. C., Kohli, B. M., Bosset, J., Meier, M., Suzuki, T., Nitsch, R. M., et al. (2004). The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci. 117, 4435–4448. doi: 10.1242/jcs.01323
246. Wakabayashi, M., Okada, T., Kozutsumi, Y., and Matsuzaki, K. (2005). GM1 ganglioside-mediated accumulation of amyloid β-protein on cell membranes. Biochem. Biophys. Res. Commun. 328, 1019–1023. doi: 10.1016/j. bbrc.2005.01.060
247. Wang, J., Cheng, A., Wakade, C., and Yu, R. K. (2014). Ganglioside GD3 is required for neurogenesis and long-term maintenance of neural stem cells in the postnatal mouse brain. J. Neurosci. 34, 13790–13800. doi: 10.1523/JNEUROSCI.2275-14.2014
248. Weisgraber, K. H., Rall, S. C. Jr., and Mahley, R. W. (1981). Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 256, 9077–9083.
249. Winkler, E., Kamp, F., Scheuring, J., Ebke, A., Fukumori, A., and Steiner, H. (2012). Generation of Alzheimer disease-associated amyloid β42/43 peptide by γ-secretase can be inhibited directly by modulation of membrane thickness. J. Biol. Chem. 287, 21326–21334. doi: 10.1074/jbc.M112.356659
250. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439–1443. doi: 10.1001/archneur.57.10.1439
251. Wolozin, B., Wang, S. W., Li, N. C., Lee, A., Lee, T. A., and Kazis, L. E. (2007). Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 5:20. doi: 10.1186/1741-7015-5-20
252. World Alzheimer Report (2015). Alzheimer’s Disease International. London: Alzheimer’s Disease International (ADI).
253. Xiong, H., Callaghan, D., Jones, A., Walker, D. G., Lue, L. F., Beach, T. G., et al. (2008). Cholesterol retention in Alzheimer’s brain is responsible for high β- and γ-secretase activities and Aβ production. Neurobiol. Dis. 29, 422–437. doi: 10.1016/j.nbd.2007.10.005
254. Yanagisawa, K., Odaka, A., Suzuki, N., and Ihara, Y. (1995). GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer’s disease. Nat. Med. 1, 1062–1066. doi: 10.1038/nm1095-1062
255. Yang, X., Sheng, W., Sun, G. Y., and Lee, J. C. (2011). Effects of fatty acid unsaturation numbers on membrane fluidity and α-secretase-dependent amyloid precursor protein processing. Neurochem. Int. 58, 321–329. doi: 10.1016/j.neuint.2010.12.004
256. Yatin, S. M., Aksenova, M., Aksenov, M., Markesbery, W. R., Aulick, T., and Butterfield, D. A. (1998). Temporal relations among amyloid β-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses. J. Mol. Neurosci. 11, 183–197. doi: 10.1385/jmn:11: 3:183
257. Yu, R. K., Tsai, Y. T., Ariga, T., and Yanagisawa, M. (2011). Structures, biosynthesis and functions of gangliosides–an overview. J. Oleo Sci. 60, 537–544. doi: 10.5650/jos.60.537
258. Zanetti, O., Solerte, S. B., and Cantoni, F. (2009). Life expectancy in Alzheimer’s disease (AD). Arch. Gerontol. Geriatr. 49, 237–243. doi: 10.1016/j.archger.2009. 09.035
259. Zeng, Y., and Han, X. (2008). Sulfatides facilitate apolipoprotein E-mediated amyloid-β peptide clearance through an endocytotic pathway. J. Neurochem. 106, 1275–1286. doi: 10.1111/j.1471-4159.2008. 05481.x
260. Zha, Q., Ruan, Y., Hartmann, T., Beyreuther, K., and Zhang, D. (2004). GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry 9, 946–952. doi: 10.1038/sj.mp.4001509